Molecular and cellular therapies against COVID-19 using angiotensin-converting enzyme 2 (ACE2) [Added supplements: COVID-19 Variant Supplement; sex as a biological variable supplement]

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 170344, 171482, 175560

Grant search

Key facts

  • Disease

  • Start & end year

  • Known Financial Commitments (USD)

  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principle Investigator

  • Research Location

    Canada, Americas
  • Lead Research Institution

    Keenan Research Centre (Toronto, ON)
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Clinical trial (unspecified trial phase)

  • Special Interest Tags


  • Study Subject


  • Clinical Trial Details


  • Broad Policy Alignment


  • Age Group


  • Vulnerable Population


  • Occupations of Interest



An epidemic caused by a novel coronavirus (SARS-CoV-2) has spread rapidly in China and 27 other countries. As of 15 February 2020, over 69,000 cases of COVID-19 have been reported, with 1,666 deaths. The enormous health, economic and social impact clearly make it paramount to better understand the pathogenesis of COVID-19, as no specific drugs are available to combat COVID-19. To address this issue we have put together a world-class international research team of basic scientists and clinicians who have a track record of working together and have access to resources [SARS-CoV-2, cell and animal models, a candidate drug, biotech company, and patients (in China)]. This research proposal focuses on the role of angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor to enter human body. We propose to do basic studies to examine the specific mechanisms involved, as well as to perform a clinical trial in COVID-19 patients in China using recombinant human ACE2 (rhACE2).